



Attorney Docket No.: 4759.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: 09/940,963

Group Art Unit: To be assigned

Filed: August 28, 2001

Examiner: To be assigned

For: Heterocyclic Compounds, Their Preparation And Use

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--Cross-reference to Related Applications

This application is a continuation of application serial no. 09/613,656 filed July 11, 2000, which in a continuation of application serial no. 09/148,637 filed September 4, 1998, now abandoned, which is a continuation application of PCT/DK97/00120 filed March 19, 1997 and claims priority under 35 U.S.C. 119 of Danish application 0322/96 filed March 19, 1996, the contents of which are fully incorporated herein by reference.--

ABSTRACT:

At the end of the application, after page 45, please insert the following:

--


ABSTRACT

The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical or veterinary compositions comprising the compounds. The novel compounds are useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.--

REMARKS

Entry of this amendment is respectfully requested. This Preliminary amendment is being filed in response to the Notice To File Corrected Application Papers mailed September 18, 2001, which indicated that an abstract was not provided for this application. By this amendment, applicants have added the Abstract at the end of the application. In addition, the Cross-reference to Related Application section has been added to the specification. Since no new matter has been added, entry of the amendment is respectfully requested.

Respectfully submitted,



Date: November 16, 2001

Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE